Abstracts Archive - Page 2109 of 2607 - ACR Meeting Abstracts

Abstract Number: 1869 • 2014 ACR/ARHP Annual Meeting
Child Pain, Function, and Psychological Outcomes in an Intensive Interdisciplinary Pediatric Pain Rehabilitation Program
Cara Hoffart¹, Rawni Anderson², Amy Chapman³, Brandi Dorton³, Danielle Feltrop³, Misty Wilson³ and Dustin Wallace⁴, ¹Rheumatology and Integrative Pain Management, Children's Mercy Hospital, Kansas City, MO, ²Medical Research, Children's Mercy Hospital, Kansas City, MO, ³Children's Mercy Hospital, Kansas City, MO, ⁴Integrative Pain Management and Developmental and Behavioral, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: We examined the functional, psychological, and pain-related outcomes among children with chronic pain completing an intensive interdisciplinary pediatric pain rehabilitation program. We hypothesized that…
Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting
Can DAS 28 at 3 Months after the 1^st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Tomohiro Kubota¹, Syuji Takei², Tsuyoshi Yamatou³, Tomokazu Nagakura⁴, Hiroyuki Imanaka³, Yukiko Nonaka³, Tomoko Takezaki³, Harumi Akaike³ and Mio Matsuura⁵, ¹8-35-1 Sakuragaoka, Kagoshima University Hospital, Kagoshima City, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Kagoshima University, Kagoshima-Shi, Japan
Background/Purpose: To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…
Abstract Number: 1867 • 2014 ACR/ARHP Annual Meeting
Mandibular Movement in Healthy Individuals from 4-17 Years of Age
Peter Stoustrup¹, Kasper Dahl Kristensen^2,3, Annelise Küseler⁴, Thomas Klit Pedersen^5,6 and Troels Herlin⁷, ¹Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, ²Section of Orthodontics, University of Aarhus, Denmark, 8000 Aarhus, Denmark, ³Specialist Oral Health Center for Western Norway, Rogaland Stavanger, Norway, ⁴Section of Orthodontics, Aarhus University, Aarhus, Denmark, ⁵Section or Orthodontics, Aarhus University, Aarhus, Denmark, ⁶Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, Aarhus, Denmark, ⁷Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Assessment of mandibular movement capacity is an important part of the clinical orofacial examination of patients with juvenile idiopathic arthritis (JIA). The aim of…
Abstract Number: 1887 • 2014 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis of Twin Pairs Discordant for Systemic Sclerosis Reveals Distinct Signatures in Blood and Dermal Fibroblasts
Paula S. Ramos¹, Rick Jordan², James Lyons-Weiler², Thomas A. Medsger Jr.³ and Carol A. Feghali-Bostwick⁴, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ³Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose Systemic sclerosis (SSc) is a chronic, multisystem, autoimmune inflammatory disease with genetic and non-genetic contributions to risk. The etiology of SSc, including the reasons…
Abstract Number: 1886 • 2014 ACR/ARHP Annual Meeting
A Novel Monocyte-Specific Transcript Underlies the Chromosome 21q22 Intergenic Genetic Association in Ankylosing Spondylitis
Katelin Haynes, Tony Kenna, Evgeny Glazov, Matthew A. Brown and Gethin Thomas, University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: A major finding of the GWAS era of common disease gene-mapping has been that observed associations more often involve intergenic locations than protein-coding regions. …
Abstract Number: 1885 • 2014 ACR/ARHP Annual Meeting
Integrative Omics Profiling Reveals Dysregulated Novel Pathways Mediated By microRNAs and DNA Methylation in Osteoarthritis
Kathleen M. Fisch¹, Ryuichiro Akagi², Oscar Alvarez-Garcia¹, Takeshi Teramura¹, Yuta Muramatsu¹, Masahiko Saito³, Stuart Duffy¹, Shawn Grogan⁴, Takahisa Sasho⁵, Darryl D'Lima⁶, Andrew I. Su¹ and Martin K. Lotz¹, ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²The Scripps Research Institute, San Diego, CA, ³Orthopaedic Surgery, Toho University Sakura Medical Center, Sakura, Japan, ⁴The Scripps Research Institute, La Jolla, CA, ⁵Orthopaedic Surgery, Chiba University School of Medicine, Chiba, Japan, ⁶SCORE, The Scripps Research Institute, La Jolla, CA
Background/Purpose: Osteoarthritis (OA) is a prevalent joint disease, with several identified clinical risk factors. However, the search for genetic risk factors by candidate gene and…
Abstract Number: 1884 • 2014 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Rheumatoid Arthritis in Disease Discordant Monozygotic Twins
Amy Webster¹, Flore Zufferey², Darren Plant³, Anne Barton^4,5, Frances Williams² and Jane Worthington^1,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Dept Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶The University of Manchester, Manchester, United Kingdom
Background/Purpose: Previous epigenetic studies of rheumatoid arthritis (RA) using prevalent cases and unrelated controls have indicated that DNA methylation is altered in patients with RA.…
Abstract Number: 1882 • 2014 ACR/ARHP Annual Meeting
Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice
Sonali N. Shah¹, Rachel Halpern², Joseph C. Cappelleri³, Elizabeth T. Masters⁴, Andrew G. Clair⁵, Cori Blauer-Peterson² and Damon Van Voorhis⁶, ¹Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, ²Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴Health Economics and Outcomes Research, Pfizer Inc, New York, NY, ⁵US Medical Affairs Primary Care, Pfizer, Inc., New York, NY, ⁶Optum Life Sciences, Eden Prairie, MN
Background/Purpose: Fibromyalgia (FM) affects 2-5% of adults in the United States. Pregabalin (antiepileptic drug [AED]), and duloxetine and milnacipran (serotonin and norepinephrine reuptake inhibitors), are…
Abstract Number: 1881 • 2014 ACR/ARHP Annual Meeting
Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: One area not assessed by studies to evaluate the efficacy of new medications in patients with inflammatory arthritis is whether the patient may have…
Abstract Number: 1850 • 2014 ACR/ARHP Annual Meeting
The Incidence and Risk Factors for Psa in Patients with Psoriasis – a Prospective Cohort Study
Lihi Eder¹, Amir Haddad¹, Hua Shen², Cheryl Rosen³, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose There are limited data regarding the incidence of PsA in patients with psoriasis. We aimed to estimate the incidence of PsA in a prospective…
Abstract Number: 1849 • 2014 ACR/ARHP Annual Meeting
Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴ and Jeffrey R. Curtis⁷, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose The introduction of biologics has greatly changed the treatment of psoriatic arthritis (PsA) and psoriasis (PsO). However, there are concerns regarding the risk of…
Abstract Number: 1848 • 2014 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition
Karen M. Fagerli^1,2, Louise K. Mercer¹, Kath D. Watson¹, Jonathon Packham³, Deborah PM Symmons^4,5, Kimme L. Hyrich⁶ and . On behalf of the BSRBR⁷, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Diakonhjemmet Hospital, Oslo, Norway, ³Institute of Science and Technology in Medicine, Keele, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose Few studies have explored risk of cancer in psoriatic arthritis (PsA). There are concerns that the risk may be raised, not only by the…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pirow Bekker¹, David Jayne², Annette Bruchfeld³, Matthias Schaier⁴, Kazimierz Ciechanowski⁵, Lorraine Harper⁶, Michel Jadoul⁷, Mårten Segelmark⁸, Daina Selga⁹, Istvan Szombati¹⁰, Michael Venning¹¹, Christian Hugo¹², Paul L. van Daele¹³, Ondrej Viklicky¹⁴, Antonia Potarca¹⁵ and Thomas J. Schall¹⁵, ¹Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, ²Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Pomeranian Medical University, Szczecin, Poland, ⁶Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁷Cliniques Saint-Luc, Brussels, Belgium, ⁸Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Budaclinic, Budapest, Hungary, ¹¹Manchester University, Manchester, United Kingdom, ¹²Dresden University, Dresden, Germany, ¹³Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ¹⁴Instit of Clin and Exp Med, Prague, Czech Republic, ¹⁵ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].